Pancreatic Cancer Research

ResearcherUniversity Hospital of BernActive in the last 2 years

Thomas Malinka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5860-5710; OpenAlex author ID A5007996953. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
100
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 17

  1. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  2. Technical Recommendation on Multi-Driver Multifrequency MR Elastography for Tomographic Mapping of Abdominal Stiffness With a Focus on the Pancreas and Pancrea… Co-author DOI 10.1097/rli.0000000000001231↗
  3. Virtual reality volumetric rendering versus cross-sectional imaging for pancreatic cancer resectability assessment: a pilot randomized controlled reader study. Co-author DOI 10.1186/s42234-026-00202-2↗
  4. Placental growth factor promotes neural invasion and predicts disease prognosis in resectable pancreatic cancer. Co-author DOI 10.1186/s13046-024-03066-z↗
  5. Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Oth… Co-author DOI 10.3390/cancers16061194↗
  6. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  7. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  8. Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients-A Single Center Analysis of 2323 Patien… Co-author DOI 10.3390/jcm12113656↗
  9. Correction: Felsenstein M. et al. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? J. Clin. Med. 2022… Last author DOI 10.3390/jcm12216947↗
  10. Influence of Baseline CT Body Composition Parameters on Survival in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm11092356↗
  11. Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies? Last author DOI 10.3390/jcm11092367↗
  12. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Co-author DOI 10.3390/jcm11164905↗
  13. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? Co-author DOI 10.3390/medicina57010077↗
  14. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. Last author DOI 10.21873/anticanres.13781↗
  15. Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. Co-author DOI 10.1016/j.ejso.2018.05.002↗
  16. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2018.09.004↗
  17. The silencing of N-myc downstream-regulated gene-1 in an orthotopic pancreatic cancer model leads to more aggressive tumor growth and metastases. Co-author DOI 10.1159/000363065↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Uwe Pelzer · 11 shared papers, 2018–2026 · strength 1.58
  2. Lea Timmermann · 7 shared papers, 2019–2026 · strength 1.02
  3. Uli Fehrenbach · 5 shared papers, 2022–2026 · strength 0.87
  4. Christopher Neumann · 4 shared papers, 2022–2024 · strength 0.67
  5. Matthäus Felsenstein · 4 shared papers, 2018–2026 · strength 0.63
  6. Marcus Bahra · 5 shared papers, 2018–2024 · strength 0.59
  7. Christian Benzing · 3 shared papers, 2022–2023 · strength 0.46
  8. Fritz Klein · 4 shared papers, 2018–2021 · strength 0.41
  9. Benjamin Struecker · 2 shared papers, 2018–2026 · strength 0.33
  10. Bruno Valentin Sinn · 2 shared papers, 2022–2023 · strength 0.28
  11. Mengwen Hu · 2 shared papers, 2022–2023 · strength 0.28
  12. Moritz Queisner · 1 shared paper, 2026 · strength 0.26
  13. Karl Eisenträger · 1 shared paper, 2026 · strength 0.26
  14. Nathalie Rosumeck · 2 shared papers, 2019–2021 · strength 0.25
  15. Hans‐Jonas Meyer · 1 shared paper, 2026 · strength 0.22
  16. Nienke Petronella Maria Wassenaar · 1 shared paper, 2026 · strength 0.22
  17. Rolf Reiter · 1 shared paper, 2026 · strength 0.22
  18. Ingolf Sack · 1 shared paper, 2026 · strength 0.22
  19. Jakob Schattenfroh · 1 shared paper, 2026 · strength 0.22
  20. Johanna Wanda Meyer-Knees · 1 shared paper, 2024 · strength 0.20
  21. Christian Fischer · 1 shared paper, 2024 · strength 0.18
  22. Andreas Göhrig · 1 shared paper, 2024 · strength 0.18
  23. Katharina M Detjen · 1 shared paper, 2024 · strength 0.18
  24. François Schneider · 1 shared paper, 2023 · strength 0.17
  25. Timm Denecke · 2 shared papers, 2018 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.